Ubs Group Ag Bria Cell Therapeutics Corp. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$4.59 - $7.99 $775 - $1,350	169 New	169 $1,000
Q2 2022 Aug 10, 2022	BUY	$4.28 - $11.9 $5,855 - $16,279	1,368 Added 450.0%	1,672 $10,000
Q1 2022 May 16, 2022	SELL	$5.91 - $10.14 $6,489 - $11,133	-1,098 Reduced 78.32%	304 $3,000
Q4 2021 Feb 14, 2022	SELL	$7.1 - $10.61 $11,892 - $17,771	-1,675 Reduced 54.44%	1,402 $12,000
Q3 2021 Nov 15, 2021	SELL	$4.4 - $9.28 $45,016 - $94,943	-10,231 Reduced 76.88%	3,077 $25,000
Q2 2021 Aug 13, 2021	BUY	$2.89 - $6.57 $36,633 - $83,281	12,676 Added 2005.7%	13,308 $71,000
Q1 2021 May 12, 2021	BUY	$3.15 - $6.17 $1,990 - $3,899	632 New	632 $2,000

Ticker BCTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,518,000
Market Cap $14.9M
Description
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.